Previous close | 66.33 |
Open | 67.40 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 67.40 - 67.50 |
52-week range | 67.40 - 67.50 |
Volume | |
Avg. volume | N/A |
Market cap | 9.944M |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | 0.52 |
EPS (TTM) | 1.30 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
If you want to know who really controls Cosmo Pharmaceuticals N.V. ( VTX:COPN ), then you'll have to look at the makeup...
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement21-Dec-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clasco
Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK). In the trial, Lumeblue™ was compared to placebo in white light colonoscopy with the purpo